A new hope to fight against Alzheimer’s disease, which is from a phase 2 clinical trial show that the medication, an antibody called BAN2401, slowed the progression of the disease and increased cognitive performance. BAN2401 is produced by the Biogen and Eisai presented details about the clinical trial in July 25, 2018, at the Alzheimer’s ...